Surgical treatment of non-functioning pancreatic islet cell tumors. J Surg Oncol 2005 Mar 01;89(3):170-85
Date
02/19/2005Pubmed ID
15719379DOI
10.1002/jso.20178Scopus ID
2-s2.0-14644435775 (requires institutional sign-in at Scopus site) 64 CitationsAbstract
Pancreatic endocrine tumors (PETs) are rare neoplasms originating from the amine precursor uptake and decarboxylation (APUD) stem cells. Although the majority of PETs are sporadic, they frequently occur in familial syndromes. PETs may cause a variety of functional syndromes or symptoms of local progression if they are non-functional. General neuroendocrine tumor markers are highly sensitive in the diagnostic assessment of a PET. Imaging studies for tumor localization and staging include computer tomography (CT) scan, magnetic resonance imaging (MRI), In(111)-octreotide scan, MIBG, and endoscopic ultrasonography (EUS). Treatment of PETs often requires a multi-modality approach; however, surgical resection remains the only curative therapy for localized (non-metastatic) disease. Treatment of metastatic disease includes biologic agents, cytotoxic chemotherapy, and liver-directed therapies.
Author List
Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DBAuthor
Douglas B. Evans MD Chair, Professor in the Surgery department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, Tumor
Carrier Proteins
Catheter Ablation
Combined Modality Therapy
Cytoskeletal Proteins
Humans
Interferon-alpha
Liver Transplantation
Molecular Chaperones
Multiple Endocrine Neoplasia Type 1
Neuroendocrine Tumors
Pancreatic Neoplasms
Somatostatin
